Sanofi operating income up 16% on bestseller drug Dupixent

div classBodysc17zpet90 cdBBJodivpReuters – French healthcare group Sanofis first quarter adjusted earnings gained 16.2 on continued sales growth of its bestselling drug Dupixent.p

pFirstquarter business operating income, or adjusted earnings before interest and tax, rose to 3.07 billion euros 3.23 billion, surpassing the average analyst estimate of 2.84 billion euros posted on the companys website.pdivdivdiv classBodysc17zpet90 cdBBJodiv

Sanofi said on Thursday that it still expects 2022 adjusted earnings per share to grow at a low doubledigit percentage.

Revenues of eczema and asthma treatment Dupixent jumped over 45 to 1.61 billion euros, beating an analyst consensus of 1.58 billion euros. 1 0.9500 eurosp

Reporting by Ludwig Burger Editing by Sudip KarGuptap

divdivdiv classBodysc17zpet90 cdBBJodivdivdiv